CREON Dosing for Infants

Dosing for infants (12 months)
with EPI due to CF

CREON® (pancrelipase) 3,000 lipase units/120 mL of formula or per breast-feeding prior to each feeding

3,000 lipase units/120 mL of formula or per
breast-feeding immediately prior to each feeding

Capsules shown are not actual size and do not represent the exact color shade. For illustrative purposes only. The active ingredient in CREON evaluated in clinical trials is lipase.

Administration

  • Caregivers should administer CREON prior to every feeding
  • The CREON capsule or its contents should not be crushed or chewed
  • Do not mix CREON capsule contents directly into formula or breast milk
  • Contents of the CREON 3,000 lipase-units capsule may be put directly in the infant’s mouth right before feeding with formula or breast milk
  • The contents of the CREON capsule can be sprinkled onto soft food like applesauce or jarred baby food. Do not store CREON that has been mixed with food
  • Give the child enough formula or breast milk to completely swallow the CREON capsule contents or CREON food mixture
  • Care should be taken to ensure that the entire dose is swallowed and not left in the mouth as it can cause irritation of the oral mucosa

Sprinkling instructions

Hold CREON® (pancrelipase) capsules upright so you can read the word CREON on the capsule

Hold the capsule upright so that you can read the word CREON on the capsule.

Carefully twist off the top portion of the capsule

Carefully twist off the top portion of the capsule.

Sprinkle the contents of the capsule directly into the infant’s mouth, or mix the contents in a small amount of room temperature acidic soft food such as applesauce or jarred baby food. Do not mix CREON with formula or bottled breast milk. If you sprinkled CREON on soft food, feed it to the child immediately. Do not store CREON that is mixed with food.

Sprinkle the contents of the capsule directly into the infant’s mouth, or mix the contents in a small amount of room temperature acidic soft food such as applesauce or jarred baby food.   Do not mix CREON with formula or bottled breast milk. If you sprinkled CREON on soft food, feed it to the child immediately. Do not store CREON that is mixed with food.

Give the child enough liquid to completely swallow the CREON contents or the CREON and food mixture. Look in the child’s mouth to make sure that all of the medicine has been swallowed. Any medicine left in the mouth may cause irritation

Give the child enough liquid to completely swallow the CREON contents or the CREON and food mixture. Look in the child’s mouth to make sure that all of the medicine has been swallowed. Any medicine left in the mouth may cause irritation.

CREON CFCareForward designed for patients and caregivers of patients with EPI due to cystic fibrosis

Help patients get nutritional, financial, and educational resources

Learn More
Request patient starter kits, product samples, and more

Request patient starter kits, product samples, and more

Contact a Rep

Indications and Important
Safety Information

Indications1

CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
    of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
    per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

  1. Reference:
  2. CREON [package insert]. North Chicago, IL: AbbVie Inc.

back to top #tbd